Granisym: Uses, Dosage & Side Effects

What Is Granisym and What Is It Used For?

Granisym contains the active substance granisetron, a potent and highly selective antagonist of 5-hydroxytryptamine type 3 (5-HT3) receptors. Granisetron belongs to the pharmacological class of antiemetics and antinauseants, specifically the serotonin (5-HT3) receptor antagonist subgroup. This class of medications revolutionized the management of chemotherapy-induced nausea and vomiting (CINV) when first introduced in the early 1990s, and granisetron remains one of the most important drugs in this category alongside ondansetron and palonosetron.

The development of 5-HT3 receptor antagonists represented a major breakthrough in supportive oncology care. Before their introduction, nausea and vomiting were among the most feared side effects of cancer chemotherapy, with highly emetogenic regimens such as cisplatin causing severe vomiting in more than 90% of untreated patients. The discovery that cytotoxic chemotherapy drugs cause the release of large amounts of serotonin (5-hydroxytryptamine, or 5-HT) from enterochromaffin cells in the gastrointestinal mucosa, and that this serotonin activates 5-HT3 receptors on vagal afferent neurons to trigger the emetic reflex, led to the targeted development of 5-HT3 receptor antagonists as antiemetics.

Granisetron exerts its antiemetic effect through a dual mechanism. Peripherally, it blocks 5-HT3 receptors located on the terminal endings of vagal afferent nerves in the wall of the small intestine. When cytotoxic drugs damage the intestinal mucosa, enterochromaffin cells release serotonin, which normally binds to these 5-HT3 receptors and sends signals via the vagus nerve to the vomiting center in the brainstem. By blocking these peripheral receptors, granisetron prevents the initiation of the emetic reflex at its source. Centrally, granisetron also blocks 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) of the area postrema, a region of the brainstem that lies outside the blood-brain barrier and acts as a sentinel for circulating emetic substances. This dual peripheral and central blockade provides comprehensive protection against chemotherapy-induced emesis.

Compared to other 5-HT3 receptor antagonists, granisetron has some distinguishing pharmacological characteristics. It demonstrates a higher binding affinity and greater selectivity for the 5-HT3 receptor than ondansetron. While ondansetron also has some affinity for 5-HT1B, 5-HT1C, alpha-1 adrenergic, and mu-opioid receptors, granisetron is essentially devoid of activity at these other receptor sites. This high selectivity may contribute to its favorable side effect profile. Granisetron has a longer duration of action than ondansetron, with a terminal elimination half-life of approximately 9–12 hours compared to 3–4 hours for ondansetron, which may provide sustained antiemetic protection.

Approved Indications

Granisym is indicated for the following clinical conditions:

• Chemotherapy-induced nausea and vomiting (CINV): Prevention and treatment of acute nausea and vomiting in patients receiving emetogenic cancer chemotherapy, including highly emetogenic regimens (e.g., cisplatin, cyclophosphamide/anthracycline combinations) and moderately emetogenic regimens (e.g., carboplatin, oxaliplatin, irinotecan). Granisetron is effective against both the acute phase (first 24 hours) and, to a lesser extent, the delayed phase (days 2–5) of CINV.
• Radiotherapy-induced nausea and vomiting (RINV): Prevention and treatment of nausea and vomiting associated with total body irradiation or abdominal radiation therapy. Radiation to the upper abdomen is particularly emetogenic, and granisetron provides significant benefit in this setting.
• Post-operative nausea and vomiting (PONV): Prevention and treatment of nausea and vomiting following surgical procedures, particularly in patients with risk factors for PONV such as female sex, history of motion sickness or previous PONV, non-smoking status, and use of volatile anesthetics or opioids.

What Should You Know Before Taking Granisym?

Contraindications

The primary contraindication to Granisym use is known hypersensitivity (allergy) to granisetron or to any of the excipients contained in the formulation. The excipients in Granisym film-coated tablets typically include lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and coating agents including hypromellose, titanium dioxide, macrogol, and polysorbate 80. If you have experienced a previous allergic reaction to granisetron or any other 5-HT3 receptor antagonist (such as ondansetron, dolasetron, or palonosetron), you should inform your doctor, as cross-sensitivity within this drug class has been reported, although it is not universal.

Allergic reactions to granisetron are uncommon but can include skin rash, urticaria (hives), pruritus (itching), and in very rare cases, anaphylactic reactions with bronchospasm, hypotension, and angioedema. If you experience signs of a severe allergic reaction after taking Granisym, seek immediate medical attention.

Warnings and Precautions

Before starting Granisym, discuss the following important considerations with your healthcare provider:

• Cardiac conditions: Granisetron, like other 5-HT3 receptor antagonists, has been associated with electrocardiographic (ECG) changes, including QT interval prolongation. While clinically significant QT prolongation is uncommon at recommended oral doses, patients with pre-existing cardiac conditions such as QT prolongation syndrome (congenital or acquired), electrolyte abnormalities (particularly hypokalemia and hypomagnesemia), congestive heart failure, or bradyarrhythmias should be monitored carefully. The risk may be increased when granisetron is used concurrently with other medications that prolong the QT interval.
• Subacute intestinal obstruction: Granisetron may mask the symptoms of a progressive ileus (bowel obstruction) because it reduces intestinal motility. In patients who have recently undergone abdominal surgery or who have signs of subacute intestinal obstruction, granisetron should be used with caution, and the patient should be monitored for signs of reduced bowel function.
• Serotonin syndrome: When granisetron is used in combination with other serotonergic drugs (such as selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], monoamine oxidase inhibitors [MAOIs], tramadol, fentanyl, lithium, or St John’s Wort), there is a risk of serotonin syndrome. This is a potentially life-threatening condition characterized by mental status changes (agitation, hallucinations, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (hyperreflexia, incoordination), and gastrointestinal symptoms (nausea, vomiting, diarrhea). If serotonin syndrome is suspected, granisetron should be discontinued and appropriate medical treatment initiated.
• Hepatic impairment: Granisetron is metabolized primarily in the liver by CYP3A4 enzymes. Patients with significant hepatic impairment may have reduced clearance of granisetron, leading to higher plasma concentrations and potentially increased risk of side effects. While no specific dose adjustment is generally required, patients with severe liver disease should be monitored more closely.
• Constipation: Granisetron can cause or worsen constipation by reducing colonic motility. This is particularly relevant in oncology patients who may already be prone to constipation due to opioid analgesics, reduced mobility, and dehydration. Patients should be advised about adequate hydration and fiber intake, and laxatives may be prescribed prophylactically.

Pregnancy and Breastfeeding

There is limited clinical data on the use of granisetron during pregnancy. Animal reproductive studies have not demonstrated direct harmful effects on fertility or fetal development. However, as with all medications, Granisym should only be used during pregnancy if the expected benefit to the mother outweighs any potential risk to the fetus. If you are pregnant, think you may be pregnant, or are planning to become pregnant, discuss the risks and benefits of antiemetic treatment with your oncologist and obstetrician.

It is not known whether granisetron or its metabolites are excreted in human breast milk. Given that many drugs are excreted in breast milk, and given the potential for adverse effects in the nursing infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medicine to the mother. Many oncology patients are advised not to breastfeed during chemotherapy regardless of antiemetic use.

Children and Adolescents

The safety and efficacy of oral granisetron have been established in pediatric patients for the prevention of chemotherapy-induced nausea and vomiting. However, the specific Granisym film-coated tablet formulation may not be suitable for all pediatric age groups due to difficulties in swallowing tablets. Children over 12 years of age can generally use the same oral dosing as adults. For younger children, intravenous granisetron formulations or oral solutions may be more appropriate. Always follow the specific dosing recommendations of the treating oncologist for pediatric patients.

Important Information About Ingredients

Granisym film-coated tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

How Does Granisym Interact with Other Drugs?

Granisetron is metabolized by the cytochrome P450 enzyme CYP3A4 in the liver, with minor contributions from CYP1A1. Unlike some other antiemetics, granisetron does not significantly inhibit or induce CYP450 enzymes at clinically relevant concentrations, which limits its potential for pharmacokinetic drug interactions. Nevertheless, several clinically relevant interactions should be considered:

Major Interactions

The most clinically significant interactions with granisetron involve serotonergic drugs and QT-prolonging medications. Serotonin syndrome is a rare but potentially life-threatening adverse drug reaction that can occur when two or more serotonergic drugs are used concurrently. In the oncology setting, this is particularly relevant because cancer patients frequently receive serotonergic medications for depression (SSRIs, SNRIs), pain management (tramadol, fentanyl), and antiemesis (granisetron). Symptoms of serotonin syndrome include agitation, confusion, rapid heart rate, dilated pupils, muscle twitching, loss of coordination, heavy sweating, diarrhea, and in severe cases, high fever and seizures. If you develop any of these symptoms, seek immediate medical attention.

The risk of QT prolongation is another important consideration, especially in oncology patients who may have electrolyte imbalances due to vomiting, diarrhea, or poor nutritional intake. Hypokalemia and hypomagnesemia significantly increase the risk of QT prolongation and should be corrected before initiating granisetron therapy. If you are taking other medications known to prolong the QT interval, your doctor may wish to monitor your heart rhythm with an electrocardiogram (ECG).

Minor Interactions

The interaction between granisetron and CYP3A4 enzyme inducers such as rifampicin and phenobarbital may lead to increased hepatic metabolism of granisetron, potentially reducing its plasma concentrations and antiemetic efficacy. While this interaction is generally considered minor because granisetron has a wide therapeutic index, patients receiving these combinations should be monitored for breakthrough nausea and vomiting. Conversely, strong CYP3A4 inhibitors such as ketoconazole may increase granisetron plasma levels, but this is generally well tolerated given the drug’s favorable safety profile at higher exposures.

Importantly, granisetron does not interact with commonly used chemotherapy drugs themselves. The antiemetic efficacy of granisetron is not affected by the type of cytotoxic agent used, although the emetogenic potential of different chemotherapy regimens determines the overall antiemetic strategy and whether granisetron should be used alone or in combination with other antiemetics. Food does not significantly affect the absorption or bioavailability of oral granisetron, so the tablets can be taken with or without meals.

What Is the Correct Dosage of Granisym?

The dosage of Granisym varies depending on the clinical indication, the emetogenic potential of the treatment being given, and individual patient factors. Always follow your doctor’s specific instructions regarding dosage, as they may adjust the dose based on your clinical situation. The film-coated tablets should be swallowed whole with a glass of water and can be taken with or without food.

Adults

For chemotherapy-induced nausea, the first dose of Granisym should be taken within one hour before the start of chemotherapy. Subsequent doses of 2 mg may be given at approximately 12-hour intervals for up to one week following chemotherapy, depending on the emetogenic potential of the regimen and the patient’s individual response. The total daily dose should not exceed 9 mg. In clinical practice, granisetron is often administered as part of a multimodal antiemetic regimen that includes dexamethasone and, for highly emetogenic chemotherapy, an NK1 receptor antagonist.

Children

For children aged 12 years and older, the same oral dosing as adults can be used. For children under 12 years of age, intravenous granisetron is generally preferred because of the difficulty in administering accurate oral doses with fixed-strength tablets. The recommended intravenous dose for pediatric patients (ages 2–16 years) is 10–40 micrograms per kilogram body weight (up to a maximum of 3 mg) given as a single dose before chemotherapy. If oral granisetron is prescribed for children, the dose should be calculated based on body weight and may require the use of an oral liquid formulation rather than the film-coated tablets.

Elderly

No specific dose adjustments are required for elderly patients. Clinical trials of granisetron in the prevention and treatment of CINV included a substantial proportion of patients aged 65 years and older, and no overall differences in safety or efficacy were observed between elderly and younger patients. However, elderly patients are more likely to have reduced hepatic and renal function, and they may be more susceptible to QT prolongation and electrolyte imbalances, so appropriate monitoring is recommended. Elderly patients should also be monitored for constipation, which is more common in this age group.

Missed Dose

Because Granisym is typically used as part of a scheduled antiemetic regimen around chemotherapy, radiotherapy, or surgery, the concept of a “missed dose” applies mainly to continuation dosing. If you forget to take a scheduled dose, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten dose. If you are unsure about your dosing schedule, contact your oncologist or pharmacist for guidance.

Overdose

There is limited experience with granisetron overdose. In clinical reports, doses of up to 38.5 mg of granisetron have been administered without significant clinical consequences beyond the expected side effects. The primary concern with overdose is the potential for QT interval prolongation and associated cardiac arrhythmias. Treatment of overdose is symptomatic and supportive. ECG monitoring should be initiated in cases of significant overdose, and electrolyte levels (particularly potassium and magnesium) should be checked and corrected. Given granisetron’s high volume of distribution and protein binding, hemodialysis is unlikely to be effective in enhancing its elimination.

What Are the Side Effects of Granisym?

Like all medicines, Granisym can cause side effects, although not everybody gets them. The majority of side effects reported with granisetron are mild to moderate in severity and are transient, resolving without specific treatment. It is important to distinguish between side effects caused by granisetron itself and symptoms related to the underlying chemotherapy, radiotherapy, or surgical procedure, which can sometimes overlap. The following side effects have been reported during clinical trials and post-marketing surveillance:

Headache is the most frequently reported side effect of granisetron, occurring in approximately 14–21% of patients in clinical trials. The headache is typically mild, occurs within the first 24 hours of dosing, and resolves spontaneously or responds to simple analgesics such as paracetamol (acetaminophen). It is worth noting that headache is also a common symptom in patients receiving chemotherapy, so the contribution of granisetron versus other factors may be difficult to determine in individual cases.

Constipation affects approximately 10–18% of patients and is related to granisetron’s mechanism of action. By blocking 5-HT3 receptors in the gastrointestinal tract, granisetron reduces intestinal motility and secretion, which can lead to decreased stool frequency and harder stools. This effect is usually mild and self-limiting, but it can be more problematic in oncology patients who are already predisposed to constipation due to concurrent opioid use, reduced physical activity, dehydration, and altered diet. Prophylactic measures including adequate fluid intake, dietary fiber, and stool softeners or laxatives may be recommended by your healthcare team.

Elevated liver enzymes (transaminases AST and ALT) have been reported as a common side effect of granisetron. These elevations are typically transient and asymptomatic, returning to normal values within a few days to weeks after discontinuation. Clinically significant hepatotoxicity is extremely rare. Your doctor may monitor liver function tests periodically during treatment, especially if you have pre-existing liver disease or are receiving hepatotoxic chemotherapy agents.

QT prolongation is a rare but clinically important side effect. While the oral formulation of granisetron at recommended doses has a lower risk of clinically significant QT prolongation than intravenous administration of higher doses, ECG monitoring may be warranted in patients with additional risk factors. If you experience symptoms such as palpitations, dizziness, fainting, or irregular heartbeat, contact your doctor immediately.

How Should You Store Granisym?

Proper storage of medications is essential to maintain their effectiveness and safety. Granisym film-coated tablets should be stored according to the following guidelines:

• Temperature: Store below 25°C (77°F). Do not freeze. Avoid exposure to excessive heat or direct sunlight, as high temperatures can degrade the active ingredient and reduce the medication’s effectiveness.
• Light and moisture protection: Store in the original blister packaging or container to protect from light and moisture. The film coating of the tablet provides some protection, but prolonged exposure to humidity can affect tablet integrity.
• Keep out of reach of children: Store Granisym in a safe place where children cannot see or reach it. Accidental ingestion by children could cause adverse effects.
• Expiry date: Do not use Granisym after the expiry date (EXP) printed on the carton and blister. The expiry date refers to the last day of that month. Using expired medications can be ineffective and potentially harmful.
• Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment and prevent accidental exposure.

If you notice any visible changes in the appearance of the tablets, such as discoloration, crumbling, or an unusual odor, do not take them and consult your pharmacist. These changes may indicate degradation of the medication.

What Does Granisym Contain?

Active Ingredient

The active ingredient in Granisym is granisetron, present as granisetron hydrochloride. Each film-coated tablet contains granisetron hydrochloride equivalent to 1 mg of granisetron base. Granisetron hydrochloride is a white to off-white crystalline powder that is freely soluble in water. Its molecular formula is C₁₈H₂₄N₄O·HCl, and it has a molecular weight of 348.87 g/mol (as the hydrochloride salt). Granisetron is chemically described as 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-carboxamide hydrochloride.

Inactive Ingredients (Excipients)

The inactive ingredients in Granisym film-coated tablets serve various pharmaceutical purposes including binding, disintegration, lubrication, and coating:

• Tablet core: Lactose monohydrate (filler/diluent), microcrystalline cellulose (binder/filler), hypromellose (binder), sodium starch glycolate (disintegrant), magnesium stearate (lubricant)
• Film coating: Hypromellose (coating agent), titanium dioxide E171 (opacifier/colorant), macrogol/polyethylene glycol (plasticizer), polysorbate 80 (surfactant/wetting agent)

The film coating protects the tablet core from moisture and light, provides a smooth surface for easier swallowing, and masks the taste of the active ingredient. The tablet is designed for immediate release, meaning that granisetron is released and absorbed rapidly after ingestion.